Portfolio company
Autolus Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Autolus
Autolus develops programmed T-cell therapies for patients with cancer and autoimmune diseases, including an approved treatment for adult B-cell acute lymphoblastic leukaemia.
Arcellx
This biotechnology company develops cell therapies to treat patients with cancer and autoimmune diseases.
Allogene Therapeutics
The company develops off-the-shelf allogeneic CAR T-cell therapies for patients with blood cancers, solid tumours and autoimmune diseases.
Century Therapeutics
This biotechnology company develops induced pluripotent stem cell-derived therapies to treat patients with cancer and autoimmune diseases.
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
Cullinan Oncology
This company develops therapies for patients living with autoimmune diseases and cancer.
Cabaletta Bio
This clinical-stage biotechnology company develops engineered T cell therapies for patients with various autoimmune diseases.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.